Thus, while promising effects of IR/IGF-1R inhibition are reported in preclinical studies, combining IR/IGF-1R inhibitors with additional therapeutics in the clinical setting may be necessary to achieve reductions in tumor size [25,26]. Here, IGF1R is linked to neoplasm.